Fosfomycin

138.06

138.06

245-463-1

2N81MY12TE

DTXSID4048480

C61772

J01XX01|J - Antiinfectives for systemic use

2931900090

70.1

-1.6

1.561g/cm3

94 °C

342.651ºC at 760 mmHg

161.03ºC

1.486

4.69e+01 g/L

LD50>5 g/kg (rats). Side effects may include diarrhea

Serum aminotransferase elevations occur in a small proportion of patients after a single oral dose of fosfomycin (1-2%), but at rates similar to those with comparator antibiotics. Nevertheless, serum enzyme elevations are mentioned as potential adverse events in the product label for fosfomycin. In addition, a small number of cases of clinically apparent liver injury attributed to fosfomycin have been published. The time to onset has been short, within one week of a single oral dose or within the first week of intravenous therapy, and the pattern of liver enzyme elevations has been mixed or hepatocellular. The injury has typically been mild and self-limited, and no cases of fatal acute liver failure, chronic hepatitis or vanishing bile duct syndrome have been convincingly linked to fosfomycin. The number of cases described has been too few to establish a typical clinical pattern, but immunoallergic features and autoimmune markers appear to be uncommon.

0% (not bound to plasma proteins)

For the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis.|FDA Label

Fosfomycin is an orally available, broad spectrum antibiotic used largely for treatment of uncomplicated urinary tract infections. Fosfomycin is associated with a low rate of transient serum enzyme during therapy and with rare cases of clinically apparent acute liver injury with jaundice.

Antiinfective Agents

Fosfomycin is a broad spectrum antibiotic that concentrates in kidney and bladder and is used to treat uncomplicated urinary tract infections. Fosfomycin also reduces nephrotoxicity and ototoxicity of platinum-containing anti-tumor agents.

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

Fosfomycin tromethamine is rapidly absorbed following oral administration and converted to fosfomycin. Oral bioavailability under fasting conditions is 37%. When given with food, oral bioavailability is reduced to 30%|Fosfomycin is excreted unchanged in both urine and feces.|136.1 ±44.1 L|16.9 +/- 3.5 L/hr

No transformation, excreted unchanged

5.7 (± 2.8) hours. The elimination half-life is 40 hours in anuric patients undergoing hemodialysis.

Fosfomycin is a phosphoenolpyruvate analogue produced by Streptomyces that irreversibly inhibits enolpyruvate transferase (MurA), which prevents the formation of N-acetylmuramic acid, an essential element of the peptidoglycan cell wall.

Fosfomycin

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients